- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
GE completes acquisitions
Several companies have taken the final steps to join GE Medical Systems. MedicaLogic, a developer of electronic medical
Several companies have taken the final steps to join GE Medical Systems. MedicaLogic, a developer of electronic medical records for outpatient care, has been acquired for $35.25 million in cash. The company's products will enable GE to extend the EMR capabilities of its Centricity IT system. The entire clinical history of the patient will be accessible to clinicians throughout the care process. The company has also acquired ViewPoint, a German-based firm whose products include documentation, image management, and reporting software for diagnostic imaging. ViewPoint technologies are focused heavily on ultrasound. The purchase of ViewPoint represents GE's third acquisition of an ultrasound business in Central Europe. In 2001, GE Medical Systems acquired the German firm EchoTech and the Austrian vendor Kretztechnik. GE also expanded its European distribution capabilities for ultrasound in late March through the acquisition of operations run by Vingmed Svenska AB and Vingmed AS in Sweden and Norway, respectively.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
